Immune Pharmaceuticals‘ anti-eotaxin-1 monoclonal antibody, bertilimumab, got a boost from a preclinical trial against DSS-induced colitis. Tomer Adar, M.D. at the Digestive Diseases Institute, Shaare Zedek Medical Center, Hebrew University of Jerusalem, recently presented a poster on entitled, Inhibition of Eotaxin-1 (CCL 11) Ameliorates DSS-Induced Colitis; A Novel Potential Therapeutic Approach for Inflammatory Bowel Disease, at the United European Gastroenterology Week being held in Be...